Federal contractor profile
THE INSTITUTE FOR CANCER RESEARCH
UEI FF1XVJMDYVR1CAGE 1RAF4Company website ↗
Active
Overview
- Legal name
- THE INSTITUTE FOR CANCER RESEARCH
- Registered location
- PHILADELPHIA, PA, USA
- Website
- Company website ↗
- Primary NAICS
- 541720 — Research and Development in the Social Sciences and Humanities
- Latest award activity
- Jul 21, 2026
Read company summary
THE INSTITUTE FOR CANCER RESEARCH is associated with UEI FF1XVJMDYVR1 and CAGE 1RAF4 in public federal records. AcornBids currently links 8 prime awards totaling $6.5M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology); Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541720 (Research and Development in the Social Sciences and Humanities). Its public SAM.gov registration lists PHILADELPHIA, PA, USA.
At a glance
Lifetime prime obligations$6.5M
Prime awards8
Awards with future end dates4
Top-agency concentration
Not available
Why this customer concentration
Detailed agency totals are not available in this stored profile.
Largest positive coded-agency total ÷ all positive coded-agency totals × 100
Missing data is shown as unavailable.
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Sep 27, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- THE INSTITUTE FOR CANCER RESEARCH
- UEI
- FF1XVJMDYVR1
- CAGE
- 1RAF4
- Registered address
- 333 COTTMAN AVE, PHILADELPHIA, PA, 19111, USA
- Registration status
- Active
- Primary NAICS
- 541720 — Research and Development in the Social Sciences and Humanities
- SAM activation
- Jan 9, 2026
- Initial registration
- Sep 11, 2000
- Entity start
- Dec 6, 1944
- SAM updated
- Jan 9, 2026
- Registration expires
- Jan 7, 2027
- Fiscal year end
- Jun 30
- Place of incorporation
- DE, USA
Federal award analysis
Net transaction obligations by federal fiscal period.
Transaction history is not available in the loaded data. Annual funding is not estimated from current award totals.
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75N91019D00022PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024 | Department of Health and Human Services | $75.0M | Jan 25, 2019 | Not available |
| 75N91022F00002TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER | Department of Health and Human Services | $1.2M | May 18, 2022 | Nov 17, 2026 |
| 75N92E21P00142THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028] | Department of Health and Human Services | $0 | May 3, 2021 | May 3, 2021 |
| 75N91024D00003PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | Department of Health and Human Services | $150.0M | Jan 25, 2024 | Not available |
| 75N91022F00001BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND… | Department of Health and Human Services | $2.1M | Jun 15, 2022 | May 14, 2027 |
| 75N91023F00003PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA | Department of Health and Human Services | $1.2M | May 3, 2023 | May 2, 2027 |
| 75N91023F00001COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS | Department of Health and Human Services | $1.0M | Jul 10, 2023 | Jul 9, 2027 |
| 75N91022F00003TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE… | Department of Health and Human Services | $948.4K | Sep 15, 2022 | Jun 14, 2026 |
Upcoming positioning windows
Modeled recompete windows are estimates, not announced solicitations or guarantees.
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Jan 9, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Sep 11, 2000 |
| Entity start | Dec 6, 1944 |
| Industry | Reported size status |
|---|---|
| 541720 — Research and Development in the Social Sciences and Humanities | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| KATHERINE LEVINS | Government business | Contact method not published | SAM registration | Not available |
| MARIA GILL | Alternate government business | Contact method not published | SAM registration | Not available |
| KATHRYN EVES | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 541720 — Research and Development in the Social Sciences and Humanities
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
158 awards
77 awards
70 awards
58 awards
54 awards
41 awards
25 awards
About THE INSTITUTE FOR CANCER RESEARCH
What products and services appear in its federal awards?
Recorded award industries: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
Recorded products and services: AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH; 6505 — Drugs and Biologicals.
Examples from recent award records:
- PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024
- TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
These records describe federal award work, not every company capability. Review the award evidence.
Where is the company registered?
333 COTTMAN AVE, PHILADELPHIA, Pennsylvania 19111, United States
Registered location from SAM.gov; award performance locations may differ.
What is its primary registered industry?
541720 — Research and Development in the Social Sciences and Humanities.
Primary SAM.gov NAICS classification.
Which federal agencies are represented in its awards?
Department of Health and Human Services.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
No official subaward rows are loaded, so Acorn does not claim known teaming relationships.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit